{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T22:32:52Z","timestamp":1794522772043,"version":"4.9.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2022-YGJC-61;2022-MS-219"],"award-info":[{"award-number":["2022-YGJC-61;2022-MS-219"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The 345 Talent Project of the Shengjing Hospital of China Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Proteasome inhibitors (PIs) are one of the most important classes of drugs for the treatment of multiple myeloma (MM). However, almost all patients with MM develop PI resistance, resulting in therapeutic failure. Therefore, the mechanisms underlying PI resistance in MM require further investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used several MM cell lines to establish PI-resistant MM cell lines. We performed RNA microarray and EccDNA-seq in MM cell lines and collected human primary MM samples to explore gene profiles. We evaluated the effect of MUC20 on cuproptosis of PI-resistant MM cells using Co-immunoprecipitation (Co-IP), Seahorse bioenergetic profiling and in vivo assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This study revealed that the downregulation of Mucin 20 (MUC20) could predict PI sensitivity and outcomes in MM patients. Besides, MUC20 attenuated PI resistance in MM cells by inducing cuproptosis via the inhibition of cyclin-dependent kinase inhibitor 2\u00a0A expression (CDKN2A), which was achieved by hindering MET proto-oncogene, receptor tyrosine kinase (MET) activation. Moreover, MUC20 suppressed MET activation by repressing insulin-like growth factor receptor-1 (IGF-1R) lactylation in PI-resistant MM cells. This study is the first to perform extrachromosomal circular DNA (eccDNA) sequencing for MM, and it revealed that eccDNA induced PI resistance by amplifying kinesin family member 3\u00a0C (KIF3C) to reduce MUC20 expression in MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings indicated that MUC20 regulated by eccDNA alleviates PI resistance of MM by modulating cuproptosis, which would provide novel strategies for the treatment of PI-resistant MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-024-02972-6","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T21:01:34Z","timestamp":1709586094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis"],"prefix":"10.1186","volume":"43","author":[{"given":"Xiaobin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuogang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"issue":"1","key":"2972_CR1","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: a cancer journal for clinicians. 2021;71(1):7\u201333.","journal-title":"CA: a cancer journal for clinicians"},{"issue":"1","key":"2972_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/hon.2586","volume":"37","author":"SV Rajkumar","year":"2019","unstructured":"Rajkumar SV. Multiple myeloma: every year a new standard? Hematol Oncol. 2019;37(1):62\u20135.","journal-title":"Hematol Oncol"},{"key":"2972_CR3","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.blre.2018.11.003","volume":"34","author":"D Vr\u00e1bel","year":"2019","unstructured":"Vr\u00e1bel D, Pour L, \u0160ev\u010d\u00edkov\u00e1 S. The impact of NF-\u03baB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Rev. 2019;34:56\u201366.","journal-title":"Blood Rev"},{"issue":"7","key":"2972_CR4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","volume":"133","author":"C Pawlyn","year":"2019","unstructured":"Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133(7):660\u201375.","journal-title":"Blood"},{"key":"2972_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","volume":"60","author":"LD Fricker","year":"2020","unstructured":"Fricker LD. Proteasome inhibitor drugs. Annu Rev Pharmacol Toxicol. 2020;60:457\u201376.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"2972_CR6","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36(4):561\u201384.","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"2972_CR7","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/bloodadvances.2022007875","volume":"7","author":"G Heynen","year":"2023","unstructured":"Heynen G, Baumgartner F, Heider M, Patra U, Holz M, Braune J, et al. SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma. Blood Adv. 2023;7(4):469\u201381.","journal-title":"Blood Adv"},{"issue":"1","key":"2972_CR8","doi-asserted-by":"publisher","first-page":"6820","DOI":"10.1038\/s41467-022-34654-2","volume":"13","author":"A Vdovin","year":"2022","unstructured":"Vdovin A, Jelinek T, Zihala D, Sevcikova T, Durech M, Sahinbegovic H, et al. The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma. Nat Commun. 2022;13(1):6820.","journal-title":"Nat Commun"},{"issue":"3","key":"2972_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s10120-022-01283-z","volume":"25","author":"L Fu","year":"2022","unstructured":"Fu L, Yonemura A, Yasuda-Yoshihara N, Umemoto T, Zhang J, Yasuda T, et al. Intracellular MUC20 variant 2 maintains mitochondrial calcium homeostasis and enhances drug resistance in gastric cancer. Gastric cancer: Official J Int Gastric Cancer Association Japanese Gastric Cancer Association. 2022;25(3):542\u201357.","journal-title":"Gastric cancer: Official J Int Gastric Cancer Association Japanese Gastric Cancer Association"},{"issue":"21","key":"2972_CR10","doi-asserted-by":"publisher","first-page":"10164","DOI":"10.1111\/jcmm.16953","volume":"25","author":"X Wang","year":"2021","unstructured":"Wang X, Shirazi F, Yan W, Liu X, Wang H, Orlowski RZ, et al. Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma. J Cell Mol Med. 2021;25(21):10164\u201374.","journal-title":"J Cell Mol Med"},{"issue":"6586","key":"2972_CR11","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254\u201361.","journal-title":"Science"},{"issue":"33","key":"2972_CR12","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1039\/D2TB01150F","volume":"10","author":"Y Lu","year":"2022","unstructured":"Lu Y, Pan Q, Gao W, Pu Y, He B. Reversal of cisplatin chemotherapy resistance by glutathione-resistant copper-based nanomedicine via cuproptosis. J Mater Chem B. 2022;10(33):6296\u2013306.","journal-title":"J Mater Chem B"},{"issue":"9","key":"2972_CR13","doi-asserted-by":"publisher","first-page":"e23145","DOI":"10.1096\/fj.202300980R","volume":"37","author":"H Wen","year":"2023","unstructured":"Wen H, Qu C, Wang Z, Gao H, Liu W, Wang H, et al. Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT\/mTOR pathway in prostate cancer. FASEB Journal: Official Publication Federation Am Soc Experimental Biology. 2023;37(9):e23145.","journal-title":"FASEB Journal: Official Publication Federation Am Soc Experimental Biology"},{"issue":"6","key":"2972_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s00011-023-01739-7","volume":"72","author":"B Xu","year":"2023","unstructured":"Xu B, Yang K, Han X, Hou J. Cuproptosis-related gene CDKN2A as a molecular target for IPF diagnosis and therapeutics. Inflamm Research: Official J Eur Histamine Res Soc [et al]. 2023;72(6):1147\u201360.","journal-title":"Inflamm Research: Official J Eur Histamine Res Soc [et al]"},{"issue":"1","key":"2972_CR15","first-page":"2249217","volume":"28","author":"H Wang","year":"2023","unstructured":"Wang H, Zhang G, Dong L, Chen L, Liang L, Ge L, et al. Identification and study of cuproptosis-related genes in prognostic model of multiple myeloma. Hematol (Amsterdam Netherlands). 2023;28(1):2249217.","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"2972_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2023.1100170","volume":"14","author":"T Li","year":"2023","unstructured":"Li T, Yao L, Hua Y, Wu Q. Comprehensive analysis of prognosis of cuproptosis-related oxidative stress genes in multiple myeloma. Front Genet. 2023;14: 1100170.","journal-title":"Front Genet"},{"key":"2972_CR17","doi-asserted-by":"publisher","first-page":"1159355","DOI":"10.3389\/fcell.2023.1159355","volume":"11","author":"B Zhang","year":"2023","unstructured":"Zhang B, Wang Q, Zhang T, Zheng Z, Lin Z, Zhou S, et al. Identification and validation of a novel cuproptosis-related gene signature in multiple myeloma. Front cell Dev Biology. 2023;11:1159355.","journal-title":"Front cell Dev Biology"},{"issue":"7890","key":"2972_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41586-021-04116-8","volume":"600","author":"KL Hung","year":"2021","unstructured":"Hung KL, Yost KE, Xie L, Shi Q, Helmsauer K, Luebeck J, et al. ecDNA hubs drive cooperative intermolecular oncogene expression. Nature. 2021;600(7890):731\u20136.","journal-title":"Nature"},{"issue":"7784","key":"2972_CR19","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s41586-019-1763-5","volume":"575","author":"S Wu","year":"2019","unstructured":"Wu S, Turner KM, Nguyen N, Raviram R, Erb M, Santini J, et al. Circular ecDNA promotes accessible chromatin and high oncogene expression. Nature. 2019;575(7784):699\u2013703.","journal-title":"Nature"},{"issue":"1","key":"2972_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12943-021-01413-8","volume":"20","author":"X Ling","year":"2021","unstructured":"Ling X, Han Y, Meng J, Zhong B, Chen J, Zhang H, et al. Small extrachromosomal circular DNA (eccDNA): major functions in evolution and cancer. Mol Cancer. 2021;20(1):113.","journal-title":"Mol Cancer"},{"key":"2972_CR21","doi-asserted-by":"publisher","first-page":"1092705","DOI":"10.3389\/fonc.2022.1092705","volume":"12","author":"J Luo","year":"2022","unstructured":"Luo J, Li Y, Zhang T, Xv T, Chen C, Li M, et al. Extrachromosomal circular DNA in cancer drug resistance and its potential clinical implications. Front Oncol. 2022;12:1092705.","journal-title":"Front Oncol"},{"issue":"2","key":"2972_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41419-022-04627-w","volume":"13","author":"C Lin","year":"2022","unstructured":"Lin C, Chen Y, Zhang F, Liu B, Xie C, Song Y. Encoding gene RAB3B exists in linear chromosomal and circular extrachromosomal DNA and contributes to cisplatin resistance of hypopharyngeal squamous cell carcinoma via inducing autophagy. Cell Death Dis. 2022;13(2):171.","journal-title":"Cell Death Dis"},{"issue":"6166","key":"2972_CR23","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1126\/science.1241328","volume":"343","author":"DA Nathanson","year":"2014","unstructured":"Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, et al. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014;343(6166):72\u20136.","journal-title":"Science"},{"issue":"11","key":"2972_CR24","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41417-022-00497-8","volume":"29","author":"X Wang","year":"2022","unstructured":"Wang X, Liu X, Wang H. Combination regimen of granulocyte colony-stimulating factor and recombinant human thrombopoietin improves the curative effect on elderly patients with leukemia through inducing pyroptosis and ferroptosis of leukemia cells. Cancer Gene Ther. 2022;29(11):1742\u201350.","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"2972_CR25","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.1038\/s41598-023-32442-6","volume":"13","author":"D Nakamura","year":"2023","unstructured":"Nakamura D. The evaluation of tumorigenicity and characterization of colonies in a soft agar colony formation assay using polymerase chain reaction. Sci Rep. 2023;13(1):5405.","journal-title":"Sci Rep"},{"issue":"1","key":"2972_CR26","doi-asserted-by":"publisher","first-page":"e000289","DOI":"10.1136\/jitc-2019-000289","volume":"8","author":"D Chen","year":"2020","unstructured":"Chen D, Barsoumian HB, Fischer G, Yang L, Verma V, Younes AI, et al. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. J Immunother Cancer. 2020;8(1):e000289.","journal-title":"J Immunother Cancer"},{"issue":"46","key":"2972_CR27","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1038\/s41388-018-0403-0","volume":"37","author":"ST Chen","year":"2018","unstructured":"Chen ST, Kuo TC, Liao YY, Lin MC, Tien YW, Huang MC. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF\/MET pathway. Oncogene. 2018;37(46):6041\u201353.","journal-title":"Oncogene"},{"issue":"7","key":"2972_CR28","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1080\/15548627.2019.1580105","volume":"15","author":"X Huang","year":"2019","unstructured":"Huang X, Gan G, Wang X, Xu T, Xie W. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. Autophagy. 2019;15(7):1258\u201379.","journal-title":"Autophagy"},{"issue":"10","key":"2972_CR29","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1042\/BCJ20190071","volume":"476","author":"T Kojima","year":"2019","unstructured":"Kojima T, Funato Y, Miki H. Phosphatase of regenerating liver sensitizes MET to functional activation by hepatocyte growth factor. Biochem J. 2019;476(10):1419\u201331.","journal-title":"Biochem J"},{"issue":"1","key":"2972_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/s41392-021-00790-2","volume":"6","author":"Y Yu","year":"2021","unstructured":"Yu Y, Peng XD, Qian XJ, Zhang KM, Huang X, Chen YH, et al. Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis. Signal Transduct Target Therapy. 2021;6(1):401.","journal-title":"Signal Transduct Target Therapy"},{"issue":"2","key":"2972_CR31","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nm.4032","volume":"22","author":"Y Du","year":"2016","unstructured":"Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016;22(2):194\u2013201.","journal-title":"Nat Med"},{"issue":"7","key":"2972_CR32","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1002\/ijc.28169","volume":"133","author":"A Varkaris","year":"2013","unstructured":"Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, et al. Ligand-independent activation of MET through IGF-1\/IGF-1R signaling. Int J Cancer. 2013;133(7):1536\u201346.","journal-title":"Int J Cancer"},{"issue":"1","key":"2972_CR33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/sj.leu.2403997","volume":"20","author":"WJ Chng","year":"2006","unstructured":"Chng WJ, Gualberto A, Fonseca R. IGF-1R is overexpressed in poor-prognostic subtypes of multiple myeloma. Leukemia. 2006;20(1):174\u20136.","journal-title":"Leukemia"},{"issue":"1","key":"2972_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41418-021-00841-9","volume":"29","author":"K Yang","year":"2022","unstructured":"Yang K, Fan M, Wang X, Xu J, Wang Y, Tu F, et al. Lactate promotes macrophage HMGB1 lactylation, acetylation, and exosomal release in polymicrobial sepsis. Cell Death Differ. 2022;29(1):133\u201346.","journal-title":"Cell Death Differ"},{"issue":"5","key":"2972_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adc9465","volume":"9","author":"M Fan","year":"2023","unstructured":"Fan M, Yang K, Wang X, Chen L, Gill PS, Ha T, et al. Lactate promotes endothelial-to-mesenchymal transition via Snail1 lactylation after myocardial infarction. Sci Adv. 2023;9(5): eadc9465.","journal-title":"Sci Adv"},{"issue":"1","key":"2972_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.canlet.2015.07.037","volume":"368","author":"C Wang","year":"2015","unstructured":"Wang C, Wang C, Wei Z, Li Y, Wang W, Li X, et al. Suppression of motor protein KIF3C expression inhibits tumor growth and metastasis in breast cancer by inhibiting TGF-\u03b2 signaling. Cancer Lett. 2015;368(1):105\u201314.","journal-title":"Cancer Lett"},{"issue":"18","key":"2972_CR37","doi-asserted-by":"publisher","first-page":"22332","DOI":"10.18632\/aging.203541","volume":"13","author":"H Ma","year":"2021","unstructured":"Ma H, Zhang F, Zhong Q, Hou J. METTL3-mediated m6A modification of KIF3C-mRNA promotes prostate cancer progression and is negatively regulated by miR-320d. Aging. 2021;13(18):22332\u201344.","journal-title":"Aging"},{"issue":"20","key":"2972_CR38","doi-asserted-by":"publisher","first-page":"8035","DOI":"10.1158\/0008-5472.CAN-09-1224","volume":"69","author":"S De","year":"2009","unstructured":"De S, Cipriano R, Jackson MW, Stark GR. Overexpression of kinesins mediates docetaxel resistance in breast cancer cells. Cancer Res. 2009;69(20):8035\u201342.","journal-title":"Cancer Res"},{"issue":"1","key":"2972_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13048-022-00983-5","volume":"15","author":"Z Marchocki","year":"2022","unstructured":"Marchocki Z, Tone A, Virtanen C, de Borja R, Clarke B, Brown T, et al. Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma. J Ovarian Res. 2022;15(1):50.","journal-title":"J Ovarian Res"},{"issue":"4","key":"2972_CR40","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.18632\/oncotarget.6554","volume":"7","author":"LY Shen","year":"2016","unstructured":"Shen LY, Wang H, Dong B, Yan WP, Lin Y, Shi Q, et al. Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling. Oncotarget. 2016;7(4):4531\u201341.","journal-title":"Oncotarget"},{"issue":"12","key":"2972_CR41","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/j.str.2011.09.021","volume":"19","author":"H Nishi","year":"2011","unstructured":"Nishi H, Hashimoto K, Panchenko AR. Phosphorylation in protein-protein binding: effect on stability and function. Structure (London, England\u202f: 1993). 2011;19(12):1807\u201315.","journal-title":"Structure (London, England : 1993)"},{"key":"2972_CR42","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.1038\/s41388-023-02795-3","volume":"42","author":"D Du","year":"2023","unstructured":"Du D, Qin M, Shi L, Liu C, Jiang J, Liao Z, et al. RNA binding motif protein 45-mediated phosphorylation enhances protein stability of ASCT2 to promote hepatocellular carcinoma progression. Oncogene. 2023;42:3127\u201341.","journal-title":"Oncogene."},{"issue":"41","key":"2972_CR43","doi-asserted-by":"publisher","first-page":"6723","DOI":"10.1038\/s41388-019-0928-x","volume":"38","author":"SY Liao","year":"2019","unstructured":"Liao SY, Kuo IY, Chen YT, Liao PC, Liu YF, Wu HY, et al. AKT-mediated phosphorylation enhances protein stability and transcription activity of ZNF322A to promote lung cancer progression. Oncogene. 2019;38(41):6723\u201336.","journal-title":"Oncogene"},{"issue":"1","key":"2972_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2022.113439","volume":"422","author":"Z Miao","year":"2023","unstructured":"Miao Z, Zhao X, Liu X. Hypoxia induced \u03b2-catenin lactylation promotes the cell proliferation and stemness of colorectal cancer through the wnt signaling pathway. Exp Cell Res. 2023;422(1): 113439.","journal-title":"Exp Cell Res"},{"issue":"8","key":"2972_CR45","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s12033-022-00643-5","volume":"65","author":"W Zhang","year":"2023","unstructured":"Zhang W, Xu L, Yu Z, Zhang M, Liu J, Zhou J. Inhibition of the glycolysis prevents the cerebral infarction progression through decreasing the lactylation levels of LCP1. Mol Biotechnol. 2023;65(8):1336\u201345.","journal-title":"Mol Biotechnol"},{"key":"2972_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2023.148373","volume":"1811","author":"L Zhang","year":"2023","unstructured":"Zhang L, Wang X, Che W, Zhou S, Feng Y. METTL3 silenced inhibited the ferroptosis development via regulating the TFRC levels in the Intracerebral hemorrhage progression. Brain Res. 2023;1811: 148373.","journal-title":"Brain Res"},{"key":"2972_CR47","doi-asserted-by":"publisher","first-page":"6349312","DOI":"10.1155\/2020\/6349312","volume":"2020","author":"Y Gao","year":"2020","unstructured":"Gao Y, Zheng H, Li L, Zhou C, Chen X, Zhou X, et al. KIF3C promotes proliferation, Migration, and Invasion of Glioma Cells by activating the PI3K\/AKT pathway and inducing EMT. Biomed Res Int. 2020;2020:6349312.","journal-title":"Biomed Res Int"},{"issue":"3","key":"2972_CR48","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s11060-020-03399-7","volume":"146","author":"Y Gao","year":"2020","unstructured":"Gao Y, Li L, Zheng H, Zhou C, Chen X, Hao B, et al. KIF3C is associated with favorable prognosis in glioma patients and may be regulated by PI3K\/AKT\/mTOR pathway. J Neurooncol. 2020;146(3):513\u201321.","journal-title":"J Neurooncol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-02972-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-024-02972-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-024-02972-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T15:03:07Z","timestamp":1709910187000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-024-02972-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2972"],"URL":"https:\/\/doi.org\/10.1186\/s13046-024-02972-6","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"15 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All human experimental procedures were approved by the Ethics Committee of Shengjing Hospital, China Medical University. Written informed consent was obtained from all participants recruited for the study. Besides, animal protocols were approved by the Institutional Animal Care and Use Committee of Shengjing Hospital, China Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"68"}}